Recent 8-K filings for LIPO

• Mar 31, 2026 23:59 UTC other_material materiality 1.00 negative item 1.03item 9.01

  Lipella Pharmaceuticals files Chapter 11 bankruptcy, plans 363 sale process

  Filed voluntary Chapter 11 petition in Western District of Pennsylvania on March 30, 2026.

• Sep 18, 2025 23:59 UTC other_material materiality 0.85 positive item 7.01item 8.01item 9.01

  Lipella reports positive Phase 2a results for LP-10 in oral lichen planus; all efficacy endpoints met

  All 27 patients completed 4-week treatment; no serious adverse events reported.

• Jun 25, 2025 23:59 UTC regulatory materiality 0.80 negative item 7.01item 8.01item 9.01

  Lipella Pharmaceuticals Delisted from Nasdaq, Plans to Relist on National Exchange

  Delisted from Nasdaq effective June 19, 2025 due to non-compliance with Listing Rules 5100, 5635, and 5640 regarding private placement transactions.

• Jun 20, 2025 23:59 UTC regulatory materiality 1.00 negative item 3.01item 7.01item 9.01

  Lipella Pharmaceuticals receives Nasdaq delisting; stock moves to OTC Markets

  Nasdaq Hearings Panel determined to delist Lipella common stock effective June 20, 2025; trading suspended.

• May 16, 2025 23:59 UTC regulatory materiality 0.70 negative item 3.01

  Lipella receives Nasdaq deficiency notice for preferred stock issuance; faces potential delisting

  Nasdaq notified Lipella that its Series C Preferred Stock and Warrant issuances violated Listing Rules 5635(d) and 5640 (shareholder approval and voting rights).

• May 15, 2025 23:59 UTC other_material materiality 0.75 positive item 7.01item 8.01item 9.01

  Lipella presents positive Phase 2a data for LP-310; 0.50mg dose shows stat-sig efficacy in OLP

  Statistically significant improvements at 0.50mg dose: IGA from 3.42 to 1.71 (p=0.007), REU from 26.91 to 11.88 (p=0.003).

• Apr 14, 2025 23:59 UTC other_material materiality 0.75 positive item 8.01

  Lipella Pharmaceuticals regains Nasdaq equity compliance after $5.9M placement

  Final closing of Series B convertible preferred stock offering on March 12, 2025; net proceeds ~$5.9M.

• Apr 07, 2025 23:59 UTC other_material materiality 0.60 neutral item 1.01item 9.01

  Lipella Pharma enters $2.64M ATM equity facility with H.C. Wainwright

  ATM agreement for up to $2,641,881 of common stock at market prices.

• Mar 18, 2025 23:59 UTC other_material materiality 0.65 neutral item 1.01item 3.02item 9.01

  Lipella completes final close of Series B offering ($88.5K) and launches March warrant offering

  Final close sold 885 shares of Series B preferred at $100/share for $88,500 gross; net proceeds $73,455.

• Mar 03, 2025 23:59 UTC other_material materiality 0.60 neutral item 1.01item 3.02item 9.01

  Lipella raises $3.79M in third closing of Series B convertible preferred offering

  Sold 37,880 Series B convertible preferred shares at $100 each; gross proceeds $3.788M, net $3.124M after fees.

• Feb 24, 2025 23:59 UTC m_and_a materiality 0.60 neutral item 1.01item 9.01

  Lipella Pharmaceuticals amends placement agent agreement with Spartan Capital Securities

  Second Amendment removes at-the-market facility restrictions and modifies tail provision to require 10% fee on investments from accredited retail investors within one year of termination.

Materiality & sentiment trend

Max materiality 1.00 · Median 0.60 · Most common event other_material

3 positive 4 negative 10 neutral

source · LIPO on sec.gov